Understand the source comparison
Comparison: Peptides vs Standard Tendon Healing Approaches
BPC-157 Peptide Upregulates VEGF receptor signaling, promotes angiogenesis and fibroblast migration 4–8 weeks in animal models (40–60% faster than controls) Multiple rat and equine studies; no human RCTs Requires injection; dosing protocols extrapolated from a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 Peptide
- Upregulates VEGF receptor signaling, promotes angiogenesis and fibroblast migration
- 4–8 weeks in animal models (40–60% faster than controls)
- Multiple rat and equine studies; no human RCTs
- Requires injection; dosing protocols extrapolated from animal research
- TB-500 Peptide
- Binds actin to promote cell migration; reduces scar tissue formation
- 6–10 weeks in equine models (30–50% improvement in collagen alignment)
- Extensive equine veterinary research; limited human data
- High cost; twice-weekly injections for 4–6 weeks
- Platelet-Rich Plasma (PRP)
- Delivers concentrated autologous growth factors to injury site
- 8–12 weeks; evidence mixed depending on preparation method
- Some human RCTs show benefit; meta-analyses inconclusive
- Requires blood draw and centrifugation; single treatment may be insufficient
- Physical Therapy + Eccentric Loading
- Mechanically stimulates collagen remodeling through controlled load
- 12–16 weeks; gold standard for chronic tendinopathy
- Strong human RCT evidence for Achilles and patellar tendinopathy
- Requires patient compliance; ineffective during acute inflammation phase
- Rest + NSAIDs
- Reduces inflammation; passive healing
- 12–24 weeks; high re-injury rate (30–40%)
- Widely used but minimal RCT support for long-term outcomes
- Does not address underlying collagen disorganization or inadequate angiogenesis